scispace - formally typeset
D

Dawei Wang

Publications -  6
Citations -  575

Dawei Wang is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 3 publications receiving 449 citations.

Papers
More filters
Journal ArticleDOI

Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study.

TL;DR: Compared with the cases in Wuhan, the cases of imported coronavirus disease-19 in Jiangsu exhibited mild or moderate symptoms and no obvious gender susceptivity, and the proportion of patients having liver dysfunction and abnormal CT imaging was relatively lower than that of WuhAn.
Journal ArticleDOI

Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study.

TL;DR: The elderly and patients with higher level of CRP were more likely to experience a severe outcome of COVID‐19, and age and c‐reactive protein (CRP) level were independent risk factors for recovery of patients with CO VID‐19 combined with HBV infection.
Journal ArticleDOI

Red cell distribution width-to-lymphocyte ratio: A novel predictor for HBV-related liver cirrhosis.

TL;DR: In this article, the diagnostic power of red cell distribution width-to-lymphocyte ratio (RLR) for HBV-related liver cirrhosis via a retrospective cohort study was evaluated using AUROC.
Journal ArticleDOI

Dynamic changes of serum metabolites associated with infection and severity of patients with acute hepatitis E infection

TL;DR: The discriminative performances of differential metabolites showed that taurocholic acid, glycocholics acid, glycochenodeoxycholate‐3‐sulfate, and docosahexaenoic acid could be used to distinguish HEV‐ALF from AHE patients.
Journal ArticleDOI

Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis

TL;DR: In summary, NORAD silencing inhibited hepatic fibrosis by suppressing HSC activation via the miR-495-3p/S1PR3 axis and protected against hepatic Fibrosis by inhibiting sphingosine 1-phosphate receptor 3 (S1 PR3) expression.